1. Lizenko M.V., Petrovskiy V., Bakhirev A.M. The ratio of the content of arachidonic and eicosapentaenoic acids in serum and low-density lipoproteins in patients with bronchial asthma and the change of this magnitude in the fasting-of dietary therapy // Voprosy meditsinskoy khimii. 1998. 44. (2). 213–218. (in Russian)
2. Motavkin P.A., Gelzer B.I. Clinical and experimental pathophysiology of the lungs. Мoscow: Nauka, 1998. 366 p. (in Russian)
3. Endakova E.A., Novgorodtseva T.P., Svetashev V.I. Modification of blood fatty acids composition in case of cardio-vascular diseases. Vladivostok: Dalnauka, 2002. 296 p. (in Russian)
4. Balode L., Strazda G., Jurka N. et al. Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease // Medicina (Kaunas). 2012. 48. (6). 292–298.
5. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification // Can. J. Biochem. Physiol. 1959. 37. 911–917.
6. Brash A.R. Arachidonic acid as a bioactive molecule // J. Clin. Invest. 2001. 107. 1339–1345.
7. Carreau J.P., Duback J.P. Adaptation of a macroscale method to the microscale for fatty acid methyl transesterification of biological lipid extract // J. Chromatogr. 1978. 151. (3). 384–390.
8. Christie W.W. Equivalent chain-lengths of methyl ester derivatives of fatty acids on gas-chromatography – a reappraisal // J. Chromatogr. 1978. 447. (2). 305–314.
9. De Castro J., Hernández-Hernández A., Rodríguez M.C. et al. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma // Platelets. 2007. 18. (1). 43–51.
10. Dodge J., Mitchell C. Hanahan D. The preparation and chemical characteristics of hemoglobin-free ghost of erythrocytes // Arch. Biochem. Biophys. 1963. 100. (1). 119–130.
11. Gangopadhyay S., Vijayan V.K., Bansal S.K. Lipids of erythrocyte membranes of COPD patients: a quantitative and qualitative study // COPD. 2012. 9. (4). 322–331.
12. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. [Accessed November 10, 2012]. Available from: http://www.goldcopd.org.
13. Haworth O., Levy B.D. Endogenous lipid mediators in the resolution of airway inflammation // Eur. Respir. J. 2007. 30. 980–992.
14. Kompauer I., Demmelmair H., Koletzko B. et al. Association of fatty acids in serum phospholipids with lung function and bronchial hyperresponsiveness in adults // Eur. J. Epidemiol. 2008. 23(3). 175–190.
15. Kostikas K., Gaga M., Papatheodorou G. et al. Leukotiene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma // Chest. 2005. 127. 155–139.
16. Novgorodtseva T.P., Karaman Y.K., Zhukova N.V. et al. Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome // Lipids in Health and Disease. 2011. 10. (82). doi:10.1186/1476-511X-10-82.
17. Schwartz J. Role of polyunsaturated fatty acids in lung disease // Am. J. Clin. Nutr. 2000. 71. (1, Suppl.). 393S–396S.
18. Stransky K., Jursik T., Vitek A., Skorepa J. An improved method of characterizing fatty acids by equivalent chain length values // J. High. Res. Chromatogr. 1992. 15. 730–740.
